U.S. Markets closed

Zealand Pharma A/S (ZEAL)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
33.90+0.35 (+1.04%)
At close: 3:59PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close33.55
Open33.14
Bid33.20 x 800
Ask43.27 x 900
Day's Range32.25 - 33.90
52 Week Range22.00 - 44.42
Volume24,025
Avg. Volume12,630
Market Cap1.444B
Beta (5Y Monthly)0.94
PE Ratio (TTM)11.29
EPS (TTM)3.00
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est38.61
  • Zealand Pharma to participate in upcoming investor conferences
    GlobeNewswire

    Zealand Pharma to participate in upcoming investor conferences

    Company announcement – No. 8 / 2021 Copenhagen, DK February 23, 2021 – Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company focused on the discovery, development and commercialization of innovative peptide-based medicines, today announced that members of its senior management team are scheduled to participate virtually in the following investor conferences in March: Credit Suisse 2021 London Global Healthcare Conference Date: Tuesday, March 2, 2021 Jefferies Pan-European Mid-Cap Virtual Conference Date: Tuesday, March 30, 2021 # # # About Zealand Pharma A/S Zealand Pharma A/S (Nasdaq: ZEAL) ("Zealand") is a biotechnology company focused on the discovery, development and commercialization of innovative peptide-based medicines. More than 10 drug candidates invented by Zealand have advanced into clinical development, of which two have reached the market. Zealand’s robust pipeline of investigational medicines includes three candidates in late stage development, and one candidate being reviewed for regulatory approval in the United States. Zealand markets V-Go®, an all-in-one basal-bolus insulin delivery option for people with diabetes. License collaborations with Boehringer Ingelheim and Alexion Pharmaceuticals create opportunity for more patients to potentially benefit from Zealand-invented peptide therapeutics.Zealand was founded in 1998 in Copenhagen, Denmark, and has presence throughout the U.S. that includes key locations in New York, Boston, and Marlborough (MA). For more information about Zealand’s business and activities, please visit www.zealandpharma.com. For further information, please contact: Zealand Pharma Investor RelationsMaeve ConneightonArgot Partners investors@zealandpharma.com Zealand Pharma Media Relations David Rosen Argot Partnersmedia@zealandpharma.com

  • Zealand Pharma to participate in SVB Leerink 9th Annual Global Healthcare Conference
    GlobeNewswire

    Zealand Pharma to participate in SVB Leerink 9th Annual Global Healthcare Conference

    Press Release – No. 7 / 2021 Copenhagen, DK and Boston, MA, February 9, 2021 – Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company focused on the discovery, development and commercialization of innovative peptide-based medicines, today announced that members of its senior management team are scheduled to participate virtually in the SVB Leerink 9th Annual Global Healthcare Conference. SVB Leerink Global Healthcare Conference Date: Wednesday, February 24, 2021 Presentation: 8:00 a.m. ET/ 2:00 p.m. CET A live webcast of the event will be available on the "Events & Presentations" page in the Investor section of the Company's website at https://www.zealandpharma.com/events-presentations. A replay of the webcast will be archived on the Company's website following the presentation. # # # About Zealand Pharma A/S Zealand Pharma A/S (Nasdaq: ZEAL) ("Zealand") is a biotechnology company focused on the discovery, development and commercialization of innovative peptide-based medicines. More than 10 drug candidates invented by Zealand have advanced into clinical development, of which two have reached the market. Zealand’s robust pipeline of investigational medicines includes three candidates in late stage development, and one candidate being reviewed for regulatory approval in the United States. Zealand markets V-Go®, an all-in-one basal-bolus insulin delivery option for people with diabetes. License collaborations with Boehringer Ingelheim and Alexion Pharmaceuticals create opportunity for more patients to potentially benefit from Zealand-invented peptide therapeutics.Zealand was founded in 1998 in Copenhagen, Denmark, and has presence throughout the U.S. that includes key locations in New York, Boston, and Marlborough (MA). For more information about Zealand’s business and activities, please visit www.zealandpharma.com. For further information, please contact: Zealand Pharma Investor Relations Maeve Conneighton Argot Partners investors@zealandpharma.com Zealand Pharma Media Relations David Rosen Argot Partners media@zealandpharma.com

  • Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons
    GlobeNewswire

    Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons

    Company announcement – No. 6/ 2021 Copenhagen, DK and Boston, MA, U.S., February 8, 2021 – Zealand Pharma A/S (“Zealand”) (Nasdaq: ZEAL) (CVR-no. 20045078) a biotechnology company focused on the discovery, development and commercialization of innovative peptide-based medicines, has received information on transactions in Zealand's shares or related securities conducted by persons discharging managerial responsibilities and/or their closely associated persons and hereby publishes the information on such transactions. Please see the attached files. # # # About Zealand Pharma A/S Zealand Pharma A/S (Nasdaq: ZEAL) ("Zealand") is a biotechnology company focused on the discovery, development, and commercialization of next generation peptide-based medicines that change the lives of people living with metabolic and gastrointestinal diseases. More than 10 drug candidates invented by Zealand have advanced into clinical development, of which two have reached the market. Zealand’s robust pipeline of investigational medicines includes three candidates in late stage development, and one candidate being reviewed for regulatory approval in the United States. Zealand markets V-Go®, an all-in-one basal-bolus insulin delivery option for people with diabetes. License collaborations with Boehringer Ingelheim and Alexion Pharmaceuticals create opportunity for more patients to potentially benefit from Zealand-invented peptide therapeutics. Zealand Pharma was founded in 1998 in Copenhagen, Denmark, and has presence throughout the U.S. that includes key locations in New York, Boston, and Marlborough (MA). For more information about Zealand Pharma’s business and activities, please visit www.zealandpharma.com. Forward-Looking Statement The above information contains forward-looking statements that provide Zealand Pharma’s expectations or forecasts of future events. Such forward-looking statements are subject to risks, uncertainties and inaccurate assumptions, which may cause actual results to differ materially from expectations set forth herein and may cause any or all of such forward-looking statements to be incorrect. If any or all of such forward-looking statements prove to be incorrect, our actual results could differ materially and adversely from those anticipated or implied by such statements. All such forward-looking statements speak only as of the date of this release and are based on information available to Zealand Pharma as of the date of this release. For further information, please contact: Zealand Pharma Investor Relations Maeve Conneighton Argot Partners investors@zealandpharma.com Zealand Pharma Media Relations David Rosen Argot Partners media@zealandpharma.com Attachments 23_210127_Notification_EDU_s 24_210127_Notifcation_MDA_s